Back to top
more

Summit Therapeutics (SMMT)

(Delayed Data from NSDQ)

$21.10 USD

21.10
2,275,322

+0.21 (1.01%)

Updated Nov 7, 2024 04:00 PM ET

After-Market: $21.10 0.00 (0.00%) 6:32 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (81 out of 251)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Balance Sheet

Research for SMMT

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

Fiscal Year End for Summit Therapeutics PLC falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 186 649 72 66 64
Receivables 3 8 24 20 14
Notes Receivable 0 0 0 0 0
Inventories 0 0 0 0 0
Other Current Assets 0 0 1 2 1
Total Current Assets 190 657 97 88 80
Net Property & Equipment 0 1 1 1 1
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 1 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 2 2 12 14 15
Deposits & Other Assets 4 1 0 0 0
Total Assets 203 664 113 103 96
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 3 0 4 6 4
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 14 16 7 4 6
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 1 20 13 9 3
Total Current Liabilities 20 39 26 20 14
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 0 1 0
Convertible Debt 0 0 0 0 0
Long-Term Debt 100 495 0 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 2 1 3 3 3
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 125 538 30 23 17
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 7 2 1 1 1
Capital Surplus 1,066 505 384 293 241
Retained Earnings -993 -378 -300 -211 -158
Other Equity -2 -2 -2 -4 -5
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 78 127 83 79 79
Total Liabilities & Shareholder's Equity 203 664 113 103 96
Total Common Equity 78 127 83 79 79
Shares Outstanding 700.80 211.00 97.70 82.50 67.10
Book Value Per Share 0.11 0.60 0.85 0.96 1.18

Fiscal Year End for Summit Therapeutics PLC falls in the month of December.

All items in Millions except Per Share data.

9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023
Assets          
Cash & Equivalents 487 326 157 186 199
Receivables 3 3 6 3 6
Notes Receivable 0 0 0 0 0
Inventories 0 0 0 0 0
Other Current Assets 0 0 0 0 0
Total Current Assets 490 329 163 190 205
Net Property & Equipment 0 0 0 0 0
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 1 1
Deferred Charges 0 0 0 0 0
Intangibles 2 2 2 2 2
Deposits & Other Assets 2 2 2 4 4
Total Assets 503 342 177 203 218
Liabilities & Shareholders Equity 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023
Notes Payable 0 0 0 0 0
Accounts Payable 3 3 6 3 3
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 26 17 13 14 7
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 26 116 1 1 100
Total Current Liabilities 59 140 23 20 114
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 0 0 0
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 100 100 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 2 3 2 1
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 65 147 133 125 119
Shareholders Equity 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023
Preferred Stock 0 0 0 0 0
Common Stock (Par) 7 7 7 7 7
Capital Surplus 1,586 1,287 1,076 1,066 1,051
Retained Earnings -1,153 -1,097 -1,037 -993 -957
Other Equity -2 -3 -2 -2 -2
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 438 195 44 78 99
Total Liabilities & Shareholder's Equity 503 342 177 203 218
Total Common Equity 438 195 44 78 99
Shares Outstanding 737.40 724.50 701.90 700.80 697.80
Book Value Per Share 0.59 0.27 0.06 0.11 0.14